Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.

Sachdeva R, Wu M, Johnson K, Kim H, Celebre A, Shahzad U, Graham MS, Kessler JA, Chuang JH, Karamchandani J, Bredel M, Verhaak R, Das S.

Sci Rep. 2019 Oct 10;9(1):14569. doi: 10.1038/s41598-019-51270-1.

2.

Differential escape mechanisms in cetuximab-resistant head and neck cancer cells.

Willey CD, Anderson JC, Trummell HQ, Naji F, de Wijn R, Yang ES, Bredel M, Thudi NK, Bonner JA.

Biochem Biophys Res Commun. 2019 Sep 10;517(1):36-42. doi: 10.1016/j.bbrc.2019.06.159. Epub 2019 Jul 13.

PMID:
31311651
3.

Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.

Fathallah-Shaykh HM, DeAtkine A, Coffee E, Khayat E, Bag AK, Han X, Warren PP, Bredel M, Fiveash J, Markert J, Bouaynaya N, Nabors LB.

PLoS Med. 2019 May 28;16(5):e1002810. doi: 10.1371/journal.pmed.1002810. eCollection 2019 May.

4.

Stereotactic radiosurgery with MLC-defined arcs: Verification of dosimetry, spatial accuracy, and end-to-end tests.

Brezovich IA, Wu X, Popple RA, Covington E, Cardan R, Shen S, Fiveash J, Bredel M, Guthrie B.

J Appl Clin Med Phys. 2019 May;20(5):84-98. doi: 10.1002/acm2.12583. Epub 2019 Apr 11.

5.

Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice.

Chemouny JM, Gleeson PJ, Abbad L, Lauriero G, Boedec E, Le Roux K, Monot C, Bredel M, Bex-Coudrat J, Sannier A, Daugas E, Vrtovsnik F, Gesualdo L, Leclerc M, Berthelot L, Ben Mkaddem S, Lepage P, Monteiro RC.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1135-1144. doi: 10.1093/ndt/gfy323.

PMID:
30462346
6.

Structural connectivity-based segmentation of the thalamus and prediction of tremor improvement following thalamic deep brain stimulation of the ventral intermediate nucleus.

Middlebrooks EH, Tuna IS, Almeida L, Grewal SS, Wong J, Heckman MG, Lesser ER, Bredel M, Foote KD, Okun MS, Holanda VM.

Neuroimage Clin. 2018;20:1266-1273. doi: 10.1016/j.nicl.2018.10.009. Epub 2018 Oct 10.

7.

Pathologic Predictors of Local Recurrence in Atypical Meningiomas Following Gross Total Resection.

Barrett OC, Hackney JR, McDonald AM, Willey CD, Bredel M, Fiveash JB.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):453-459. doi: 10.1016/j.ijrobp.2018.09.019. Epub 2018 Sep 22.

PMID:
30253235
8.

The virtual cone: A novel technique to generate spherical dose distributions using a multileaf collimator and standardized control-point sequence for small target radiation surgery.

Popple RA, Wu X, Brezovich IA, Markert JM, Guthrie BL, Thomas EM, Bredel M, Fiveash JB.

Adv Radiat Oncol. 2018 Mar 2;3(3):421-430. doi: 10.1016/j.adro.2018.02.011. eCollection 2018 Jul-Sep.

9.

MicroRNA-31 is required for astrocyte specification.

Meares GP, Rajbhandari R, Gerigk M, Tien CL, Chang C, Fehling SC, Rowse A, Mulhern KC, Nair S, Gray GK, Berbari NF, Bredel M, Benveniste EN, Nozell SE.

Glia. 2018 May;66(5):987-998. doi: 10.1002/glia.23296. Epub 2018 Jan 30.

10.

A method for pre-operative single-subject thalamic segmentation based on probabilistic tractography for essential tremor deep brain stimulation.

Middlebrooks EH, Holanda VM, Tuna IS, Deshpande HD, Bredel M, Almeida L, Walker HC, Guthrie BL, Foote KD, Okun MS.

Neuroradiology. 2018 Mar;60(3):303-309. doi: 10.1007/s00234-017-1972-2. Epub 2018 Jan 6.

PMID:
29307012
11.

Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal disease.

Foreman PM, Jackson BE, Singh KP, Romeo AK, Guthrie BL, Fisher WS, Riley KO, Markert JM, Willey CD, Bredel M, Fiveash JB.

J Clin Neurosci. 2018 Mar;49:48-55. doi: 10.1016/j.jocn.2017.12.009. Epub 2017 Dec 14.

12.

Fractionated stereotactic radiation therapy for intact brain metastases.

Marcrom SR, McDonald AM, Thompson JW, Popple RA, Riley KO, Markert JM, Willey CD, Bredel M, Fiveash JB.

Adv Radiat Oncol. 2017 Jul 19;2(4):564-571. doi: 10.1016/j.adro.2017.07.006. eCollection 2017 Oct-Dec.

13.

Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.

Müller-Greven G, Carlin CR, Burgett ME, Ahluwalia MS, Lauko A, Nowacki AS, Herting CJ, Qadan MA, Bredel M, Toms SA, Lathia JD, Hambardzumyan D, Sarkaria JN, Hamerlik P, Gladson CL.

Clin Cancer Res. 2017 Nov 15;23(22):7059-7071. doi: 10.1158/1078-0432.CCR-17-0249. Epub 2017 Sep 14.

14.

Distant brain recurrence in patients with five or more newly diagnosed brain metastases treated with focal stereotactic radiotherapy alone.

Barrett OC, McDonald AM, Thompson JW, Bredel M, McGwin G, Riley KO, Fiveash JB.

J Radiosurg SBRT. 2017;4(4):255-263.

15.

Epigenetic Regulation of ZBTB18 Promotes Glioblastoma Progression.

Fedele V, Dai F, Masilamani AP, Heiland DH, Kling E, Gätjens-Sanchez AM, Ferrarese R, Platania L, Soroush D, Kim H, Nelander S, Weyerbrock A, Prinz M, Califano A, Iavarone A, Bredel M, Carro MS.

Mol Cancer Res. 2017 Aug;15(8):998-1011. doi: 10.1158/1541-7786.MCR-16-0494. Epub 2017 May 16.

16.

KLF6 depletion promotes NF-κB signaling in glioblastoma.

Masilamani AP, Ferrarese R, Kling E, Thudi NK, Kim H, Scholtens DM, Dai F, Hadler M, Unterkircher T, Platania L, Weyerbrock A, Prinz M, Gillespie GY, Harsh GR IV, Bredel M, Carro MS.

Oncogene. 2017 Jun 22;36(25):3562-3575. doi: 10.1038/onc.2016.507. Epub 2017 Feb 6.

17.

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A.

JAMA Oncol. 2017 Jun 1;3(6):784-792. doi: 10.1001/jamaoncol.2016.6020.

18.

A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.

Raizer JJ, Chandler JP, Ferrarese R, Grimm SA, Levy RM, Muro K, Rosenow J, Helenowski I, Rademaker A, Paton M, Bredel M.

J Neurooncol. 2016 Aug;129(1):139-46. doi: 10.1007/s11060-016-2156-3. Epub 2016 Jun 14.

PMID:
27300524
19.

Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition.

Bonner JA, Trummell HQ, Bonner AB, Willey CD, Bredel M, Yang ES.

BMC Cancer. 2015 Oct 12;15:673. doi: 10.1186/s12885-015-1679-x.

20.

Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma.

Rajbhandari R, McFarland BC, Patel A, Gerigk M, Gray GK, Fehling SC, Bredel M, Berbari NF, Kim H, Marks MP, Meares GP, Sinha T, Chuang J, Benveniste EN, Nozell SE.

Oncotarget. 2015 Jul 10;6(19):17805-16.

21.

Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience.

Clark GM, McDonald AM, Nabors LB, Fathalla-Shaykh H, Han X, Willey CD, Markert JM, Guthrie BL, Bredel M, Fiveash JB.

Neurooncol Pract. 2014 Dec;1(4):172-177.

22.

Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.

Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, Gibson EM, Mount CW, Polepalli J, Mitra SS, Woo PJ, Malenka RC, Vogel H, Bredel M, Mallick P, Monje M.

Cell. 2015 May 7;161(4):803-16. doi: 10.1016/j.cell.2015.04.012. Epub 2015 Apr 23.

23.

A20 expressing tumors and anticancer drug resistance.

da Silva CG, Minussi DC, Ferran C, Bredel M.

Adv Exp Med Biol. 2014;809:65-81. Review.

PMID:
25302366
24.

Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy.

Artesi M, Kroonen J, Bredel M, Nguyen-Khac M, Deprez M, Schoysman L, Poulet C, Chakravarti A, Kim H, Scholtens D, Seute T, Rogister B, Bours V, Robe PA.

Neuro Oncol. 2015 Mar;17(3):392-406. doi: 10.1093/neuonc/nou215. Epub 2014 Aug 25.

25.

Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.

Ferrarese R, Harsh GR 4th, Yadav AK, Bug E, Maticzka D, Reichardt W, Dombrowski SM, Miller TE, Masilamani AP, Dai F, Kim H, Hadler M, Scholtens DM, Yu IL, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, von Elverfeldt D, Backofen R, Weyerbrock A, Duarte CW, He X, Prinz M, Chandler JP, Vogel H, Chakravarti A, Rich JN, Carro MS, Bredel M.

J Clin Invest. 2014 Jul;124(7):2861-76. doi: 10.1172/JCI68836. Epub 2014 May 27.

26.

Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.

Anderson JC, Duarte CW, Welaya K, Rohrbach TD, Bredel M, Yang ES, Choradia NV, Thottassery JV, Yancey Gillespie G, Bonner JA, Willey CD.

Radiother Oncol. 2014 Jun;111(3):468-74. doi: 10.1016/j.radonc.2014.04.010. Epub 2014 May 8.

27.

Feature selection and survival modeling in The Cancer Genome Atlas.

Kim H, Bredel M.

Int J Nanomedicine. 2013;8 Suppl 1:57-62. doi: 10.2147/IJN.S40733. Epub 2013 Sep 16.

28.

Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation.

Jamshidi N, Diehn M, Bredel M, Kuo MD.

Radiology. 2014 Jan;270(1):1-2. doi: 10.1148/radiol.13130078. Epub 2013 Oct 28.

29.

Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.

Zheng Y, McFarland BC, Drygin D, Yu H, Bellis SL, Kim H, Bredel M, Benveniste EN.

Clin Cancer Res. 2013 Dec 1;19(23):6484-94. doi: 10.1158/1078-0432.CCR-13-0265. Epub 2013 Sep 13.

30.

Laminin alpha 2 enables glioblastoma stem cell growth.

Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MR, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, Nakano I, Sloan AE, Phillips HS, Lai A, Gladson CL, Bredel M, Bao S, Hjelmeland AB, Rich JN.

Ann Neurol. 2012 Nov;72(5):766-78. doi: 10.1002/ana.23674.

31.

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.

Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1206-11. doi: 10.1016/j.ijrobp.2012.10.008. Epub 2012 Nov 22.

32.

Glioblastoma multiforme.

Sheehan JM, Cavaliere R, Farace E, Bredel M, Burri SH.

Neurol Res Int. 2012;2012:819304. doi: 10.1155/2012/819304. Epub 2012 May 3. No abstract available.

33.

Gene-protein correlation in single cells.

Renfrow JJ, Scheck AC, Dhawan NS, Lukac PJ, Vogel H, Chandler JP, Raizer JJ, Harsh GR, Chakravarti A, Bredel M.

Neuro Oncol. 2011 Aug;13(8):880-5. doi: 10.1093/neuonc/nor071.

34.

Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.

Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich JN.

Cell. 2011 Jul 8;146(1):53-66. doi: 10.1016/j.cell.2011.06.006.

35.

Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.

Shankavaram UT, Bredel M, Burgan WE, Carter D, Tofilon P, Camphausen K.

J Cell Mol Med. 2012 Mar;16(3):545-54. doi: 10.1111/j.1582-4934.2011.01345.x.

36.

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, Bredel M, Stark GR, Rich JN, Bao S.

Cancer Cell. 2011 Apr 12;19(4):498-511. doi: 10.1016/j.ccr.2011.03.004.

37.

NFKBIA deletion in glioblastomas.

Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR 4th.

N Engl J Med. 2011 Feb 17;364(7):627-37. doi: 10.1056/NEJMoa1006312. Epub 2010 Dec 22.

38.

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.

Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J, Bredel M.

Cancer. 2010 Nov 15;116(22):5297-305. doi: 10.1002/cncr.25462.

39.

Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.

Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M, Bours V.

BMC Cancer. 2009 Oct 19;9:372. doi: 10.1186/1471-2407-9-372.

40.

Translating biological insights into clinical endpoints in neuro-oncology.

Bredel M.

Lancet Oncol. 2009 Oct;10(10):928-9. doi: 10.1016/S1470-2045(09)70192-5. Epub 2009 Jul 21. No abstract available.

PMID:
19628430
41.

Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.

Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M.

JAMA. 2009 Jul 15;302(3):276-89. doi: 10.1001/jama.2009.1022.

42.

A network model of a cooperative genetic landscape in brain tumors.

Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, Sikic BI.

JAMA. 2009 Jul 15;302(3):261-75. doi: 10.1001/jama.2009.997.

43.

Genomics of human intracranial aneurysm wall.

Shi C, Awad IA, Jafari N, Lin S, Du P, Hage ZA, Shenkar R, Getch CC, Bredel M, Batjer HH, Bendok BR.

Stroke. 2009 Apr;40(4):1252-61. doi: 10.1161/STROKEAHA.108.532036. Epub 2009 Feb 19.

PMID:
19228845
44.

Use of gene signatures to improve risk estimation in cancer.

Huang CC, Bredel M.

JAMA. 2008 Apr 2;299(13):1605-6. doi: 10.1001/jama.299.13.1605. No abstract available.

PMID:
18387936
45.

Nomograms as clinicobiological predictors of survival in glioblastoma.

Bredel M.

Lancet Oncol. 2008 Jan;9(1):5-6. doi: 10.1016/S1470-2045(07)70390-X. No abstract available.

PMID:
18177813
46.

Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors.

Juric D, Bredel C, Sikic BI, Bredel M.

Methods Mol Biol. 2007;377:187-202. Review.

PMID:
17634618
47.

CHD5 is a tumor suppressor at human 1p36.

Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills AA.

Cell. 2007 Feb 9;128(3):459-75.

48.

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.

Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI.

J Clin Oncol. 2006 Jan 10;24(2):274-87. Epub 2005 Dec 19.

PMID:
16365179
49.

Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.

Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI.

Cancer Res. 2005 Oct 1;65(19):8679-89.

50.

High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.

Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI.

Cancer Res. 2005 May 15;65(10):4088-96.

Supplemental Content

Loading ...
Support Center